DE60231295D1 - R und ppar modulatoren - Google Patents
R und ppar modulatorenInfo
- Publication number
- DE60231295D1 DE60231295D1 DE60231295T DE60231295T DE60231295D1 DE 60231295 D1 DE60231295 D1 DE 60231295D1 DE 60231295 T DE60231295 T DE 60231295T DE 60231295 T DE60231295 T DE 60231295T DE 60231295 D1 DE60231295 D1 DE 60231295D1
- Authority
- DE
- Germany
- Prior art keywords
- ppar modulators
- ppar
- modulators
- diabetes
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
- A61K31/31—Mercury compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28142901P | 2001-04-04 | 2001-04-04 | |
PCT/US2002/010538 WO2002080936A1 (en) | 2001-04-04 | 2002-04-03 | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60231295D1 true DE60231295D1 (de) | 2009-04-09 |
Family
ID=23077253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60231295T Expired - Lifetime DE60231295D1 (de) | 2001-04-04 | 2002-04-03 | R und ppar modulatoren |
Country Status (11)
Country | Link |
---|---|
US (3) | US20030045553A1 (de) |
EP (2) | EP2065044A1 (de) |
JP (1) | JP4590159B2 (de) |
CN (1) | CN100577175C (de) |
AT (1) | ATE423559T1 (de) |
CA (1) | CA2442917C (de) |
DE (1) | DE60231295D1 (de) |
ES (1) | ES2321815T3 (de) |
MY (1) | MY180762A (de) |
TW (1) | TWI330084B (de) |
WO (1) | WO2002080936A1 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE442148T1 (de) | 2001-04-04 | 2009-09-15 | Ortho Mcneil Janssen Pharm | Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren |
DE60231295D1 (de) | 2001-04-04 | 2009-04-09 | Ortho Mcneil Janssen Pharm | R und ppar modulatoren |
US20090162342A1 (en) * | 2001-06-07 | 2009-06-25 | Sanomune Inc. | Therapeutic uses of glandular kallikrein |
EP1388352A1 (de) * | 2002-08-08 | 2004-02-11 | Laboratoires Fournier S.A. | Verwendung eines ppar-alpha-Agonisten zur Behandlung von Patienten, die an mit ppar-gamma-Agonisten-Behandlung assozierter Fettleibigkeit leiden |
DE10258008B4 (de) * | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
JP2004300102A (ja) * | 2003-03-31 | 2004-10-28 | Kissei Pharmaceut Co Ltd | 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
WO2004108126A1 (en) * | 2003-06-06 | 2004-12-16 | Snowden Pharmaceuticals, Llc | Fibric acid derivatives for the treatment of irritable bowel syndrome |
EP1638554A1 (de) * | 2003-06-27 | 2006-03-29 | Dr. Reddy's Research Foundation | Zusammensetzungen mit balaglitazon und weiteren antidiabetischen verbindungen |
EP1662906A1 (de) * | 2003-09-23 | 2006-06-07 | DSM IP Assets B.V. | Zusammensetzungen für die behandlung und vorbeugung von diabetes mellitus |
US20050239706A1 (en) * | 2003-10-31 | 2005-10-27 | Washington University In St. Louis | Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject |
CN1921843A (zh) * | 2004-01-23 | 2007-02-28 | 独立行政法人科学技术振兴机构 | 含视黄酸的糖尿病治疗药 |
CA2555316A1 (en) * | 2004-02-09 | 2005-08-18 | Aska Pharmaceutical Co., Ltd. | Combined pharmaceutical composition |
EP1727529B1 (de) | 2004-03-17 | 2016-03-02 | Lars Michael Larsen | Prävention von retinopathie durch hemmung des sehzyklus |
US20080045466A1 (en) | 2004-07-21 | 2008-02-21 | Kenji Katsuno | Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat |
WO2006096398A2 (en) * | 2005-03-03 | 2006-09-14 | Smithkline Beecham Corporation | Medicaments |
CA2623938A1 (en) * | 2005-09-30 | 2007-04-05 | Perlegen Sciences, Inc. | Methods and compositions for screening and treatment of disorders of blood glucose regulation |
EP1785133A1 (de) * | 2005-11-10 | 2007-05-16 | Laboratoires Fournier S.A. | Verwendung von Fenofibrate oder dessen Derivaten zur Prävention von diabetischer retinopathie |
DE102006028862A1 (de) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-Amino-imidazo[1,2-a]pyridinderivate |
WO2008096769A1 (ja) * | 2007-02-08 | 2008-08-14 | Daiichi Sankyo Company, Limited | 置換されたセルコスポラミド誘導体を含有する医薬 |
DE102007008420A1 (de) | 2007-02-21 | 2008-08-28 | Merck Patent Gmbh | Benzimidazolderivate |
US8666671B2 (en) * | 2007-07-05 | 2014-03-04 | Enhanced Pharmaceuticals, Inc. | Method for determining drug-molecular combinations that modulate and enhance the therapeutic safety and efficacy of biological or pharmaceutical drugs |
DE102007048716A1 (de) | 2007-10-11 | 2009-04-23 | Merck Patent Gmbh | Imidazo[1,2-a]pyrimidinderivate |
JP5302900B2 (ja) | 2008-01-31 | 2013-10-02 | アステラス製薬株式会社 | 脂肪性肝疾患の治療用医薬組成物 |
DE102008017590A1 (de) | 2008-04-07 | 2009-10-08 | Merck Patent Gmbh | Glucopyranosidderivate |
ME01285A (me) * | 2008-08-28 | 2013-06-20 | Pfizer | Derivati dioksa-bicikl0[3.2.1]oktan-2,3,4-triola |
RS53761B1 (en) | 2009-04-16 | 2015-06-30 | Taisho Pharmaceutical Co. Ltd. | PHARMACEUTICAL PREPARATIONS WITH (1S) -1,5-ANHYDRO-1- [5- (4-Ethoxybenzyl) -2-methoxy-4-methylphenyl] -1-thio-D-GLUCITOL AND INSULIN SECRETAGOGY |
JP5902619B2 (ja) * | 2009-07-10 | 2016-04-13 | ケース ウェスタン リザーブ ユニバーシティCase Western Reserve University | Rxrアゴニスト化合物および方法 |
JP2013506635A (ja) | 2009-10-02 | 2013-02-28 | サノフイ | 骨疾患を処置するための薬剤を製造するためのsglt−1/sglt−2阻害剤活性を有する化合物の使用 |
US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
CA2777857C (en) | 2009-11-02 | 2014-12-02 | Pfizer Inc. | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
ES2667854T3 (es) * | 2011-07-07 | 2018-05-14 | Holy Stone Healthcare Co., Ltd. | Composición para uso en el tratamiento y la prevención de trastornos relacionados con la inflamación |
US9451987B2 (en) | 2011-11-16 | 2016-09-27 | K2M, Inc. | System and method for spinal correction |
WO2013173923A1 (en) | 2012-05-25 | 2013-11-28 | Diamedica, Inc. | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
CA2880085C (en) | 2012-06-04 | 2021-09-07 | Diamedica Inc. | Human tissue kallikrein 1 glycosylation isoforms |
CN102727477B (zh) * | 2012-06-14 | 2014-07-16 | 合肥博太医药生物技术发展有限公司 | 视黄酸及其衍生物在制备防治糖尿病药物中的应用 |
EP2774619B1 (de) | 2013-03-04 | 2016-05-18 | BioActive Food GmbH | Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen |
EP2944311A1 (de) | 2014-05-16 | 2015-11-18 | BioActive Food GmbH | Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen |
CN110446501A (zh) | 2017-03-09 | 2019-11-12 | 代阿麦迪卡股份有限公司 | 组织激肽释放酶1的剂型 |
US20210059997A1 (en) * | 2017-12-28 | 2021-03-04 | University Of Fukui | Prophylactic agent and/or therapeutic agent for cataract, medicinal composition for preventing and/or treating cataract, use of ppar activator for producing same, and eyedrops |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
EP0842925A1 (de) * | 1987-09-04 | 1998-05-20 | Beecham Group Plc | Substituierte Thiazolidindionderivate |
JPH0253573A (ja) * | 1988-08-11 | 1990-02-22 | Nippon Riki Kk | ラチェットレンチの製造法 |
US5731299A (en) * | 1992-05-29 | 1998-03-24 | The Procter & Gamble Company | Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
JP2762903B2 (ja) | 1992-11-12 | 1998-06-11 | 田辺製薬株式会社 | ジヒドロカルコン誘導体及びその製法 |
US5731292A (en) * | 1992-11-12 | 1998-03-24 | Tanabe Seiyaku Co., Ltd. | Dihydrochalcone derivatives which are hypoglycemic agents |
CA2102591C (en) | 1992-11-12 | 2000-12-26 | Kenji Tsujihara | Hypoglycemic agent |
JP2795162B2 (ja) | 1993-02-18 | 1998-09-10 | 田辺製薬株式会社 | ジヒドロカルコン誘導体及びその製法 |
JP2906978B2 (ja) * | 1993-02-25 | 1999-06-21 | 田辺製薬株式会社 | 血糖降下剤 |
US6046222A (en) * | 1993-09-15 | 2000-04-04 | Warner-Lambert Company | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
US5830873A (en) * | 1994-05-11 | 1998-11-03 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivative and a process for preparing the same |
JP2847695B2 (ja) * | 1994-05-11 | 1999-01-20 | 田辺製薬株式会社 | 血糖降下剤 |
ES2216062T3 (es) | 1995-09-18 | 2004-10-16 | Ligand Pharmaceuticals, Inc. | Tratamiento de la niddm con agonistas del rxr. |
JP3059088B2 (ja) | 1995-11-07 | 2000-07-04 | 田辺製薬株式会社 | プロピオフェノン誘導体およびその製法 |
AU3552697A (en) | 1996-07-12 | 1998-02-09 | Smithkline Beecham Plc | Novel treatment of leptine resistance |
JP3055135B2 (ja) * | 1996-12-26 | 2000-06-26 | 田辺製薬株式会社 | プロピオフェノン誘導体及びその製法 |
ATE216704T1 (de) | 1996-12-26 | 2002-05-15 | Tanabe Seiyaku Co | Propiophenonderivate und verfahren zu ihrer herstellung |
US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
JP4100734B2 (ja) | 1997-04-30 | 2008-06-11 | Sabicイノベーティブプラスチックスジャパン合同会社 | 熱可塑性樹脂組成物 |
IL133138A0 (en) | 1997-06-18 | 2001-03-19 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor |
JP2000080041A (ja) | 1998-03-09 | 2000-03-21 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
TR200202103T2 (tr) * | 1998-11-20 | 2002-11-21 | Mitsubishi Chemical Corporation | ''5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri'' |
US6337426B1 (en) | 1998-11-23 | 2002-01-08 | Nalco/Exxon Energy Chemicals, L.P. | Antifoulant compositions and processes |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
TWI249401B (en) | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
AU4649600A (en) | 1999-04-22 | 2000-11-10 | Joel F. Habener | Bridge-1, a transcription factor |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
JP3989730B2 (ja) | 1999-08-31 | 2007-10-10 | キッセイ薬品工業株式会社 | グルコピラノシルオキシピラゾール誘導体、それを含有する医薬組成物およびその製造中間体 |
IL148361A0 (en) | 1999-08-31 | 2002-09-12 | Maxia Pharmaceuticals Inc | Benzylidene-thiazolidinedione derivatives and pharmaceutical compositions containing the same |
PE20010580A1 (es) | 1999-09-03 | 2001-05-25 | Takeda Chemical Industries Ltd | Composicion farmaceutica para tratar la diabetes |
PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
TW558554B (en) | 1999-10-29 | 2003-10-21 | Takeda Chemical Industries Ltd | Crystals of oxyiminoalkanoic acid derivative |
JP2001192375A (ja) * | 1999-10-29 | 2001-07-17 | Takeda Chem Ind Ltd | オキシイミノアルカン酸誘導体の結晶 |
PT1228067E (pt) * | 1999-11-10 | 2004-11-30 | Takeda Chemical Industries Ltd | Compostos heterociclicos de cinco membros com actividade hipoglicemica e hipolipidemica |
US6555519B2 (en) * | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
DK1333887T3 (da) * | 2000-10-30 | 2006-11-13 | Ortho Mcneil Pharm Inc | Kombinationsbehandling omfattende antidiabetiske og antikonvulsive midler |
CN1238363C (zh) * | 2000-12-28 | 2006-01-25 | 橘生药品工业株式会社 | 吡喃葡糖氧基吡唑衍生物及其在药物中的应用 |
ATE442148T1 (de) * | 2001-04-04 | 2009-09-15 | Ortho Mcneil Janssen Pharm | Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren |
DE60231295D1 (de) | 2001-04-04 | 2009-04-09 | Ortho Mcneil Janssen Pharm | R und ppar modulatoren |
-
2002
- 2002-04-03 DE DE60231295T patent/DE60231295D1/de not_active Expired - Lifetime
- 2002-04-03 EP EP09075012A patent/EP2065044A1/de not_active Withdrawn
- 2002-04-03 WO PCT/US2002/010538 patent/WO2002080936A1/en active Application Filing
- 2002-04-03 CN CN02811137A patent/CN100577175C/zh not_active Expired - Lifetime
- 2002-04-03 CA CA2442917A patent/CA2442917C/en not_active Expired - Lifetime
- 2002-04-03 ES ES02717766T patent/ES2321815T3/es not_active Expired - Lifetime
- 2002-04-03 JP JP2002578975A patent/JP4590159B2/ja not_active Expired - Fee Related
- 2002-04-03 EP EP02717766A patent/EP1381361B1/de not_active Expired - Lifetime
- 2002-04-03 AT AT02717766T patent/ATE423559T1/de not_active IP Right Cessation
- 2002-04-03 US US10/115,827 patent/US20030045553A1/en not_active Abandoned
- 2002-04-04 MY MYPI20021224A patent/MY180762A/en unknown
- 2002-04-04 TW TW091106918A patent/TWI330084B/zh not_active IP Right Cessation
-
2003
- 2003-03-24 US US10/395,502 patent/US20030199557A1/en not_active Abandoned
-
2007
- 2007-10-24 US US11/923,120 patent/US8278268B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
TWI330084B (en) | 2010-09-11 |
US8278268B2 (en) | 2012-10-02 |
EP2065044A1 (de) | 2009-06-03 |
EP1381361B1 (de) | 2009-02-25 |
US20030045553A1 (en) | 2003-03-06 |
WO2002080936A1 (en) | 2002-10-17 |
ATE423559T1 (de) | 2009-03-15 |
JP4590159B2 (ja) | 2010-12-01 |
US20030199557A1 (en) | 2003-10-23 |
JP2004529915A (ja) | 2004-09-30 |
CA2442917C (en) | 2011-02-01 |
MY180762A (en) | 2020-12-08 |
CA2442917A1 (en) | 2002-10-17 |
US20080096802A1 (en) | 2008-04-24 |
EP1381361A1 (de) | 2004-01-21 |
CN100577175C (zh) | 2010-01-06 |
ES2321815T3 (es) | 2009-06-12 |
CN1568190A (zh) | 2005-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60231295D1 (de) | R und ppar modulatoren | |
DE60233655D1 (de) | R und retinoid x rezeptorenmodulatoren | |
DE60121988D1 (de) | Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln | |
PT1349856E (pt) | Compostos de isoindolina-1-ona activadores da glicocinase | |
DE60019473D1 (de) | (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien | |
PL397846A1 (pl) | Leczenie zaburzeń związanych z TNFα | |
NO20041917L (no) | Spesifikke midler som binder humant angiopoietin-2 | |
ATE455092T1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
IL194950A0 (en) | Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders | |
DE60237823D1 (de) | Medizinisches behandlungsinstrument | |
NO20052009D0 (no) | Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom | |
ATE410165T1 (de) | Nociceptin-analoga | |
NO20022087L (no) | Fremgangsmåte for behandling av diabetes | |
NO20051521L (no) | Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt | |
CY1107531T1 (el) | Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου | |
NO20045554L (no) | Fremgangsmate for behandling av diabetes | |
SE9904377D0 (sv) | Pharmaceutical combinations | |
NO20015772L (no) | Forbindelser og fremgangsmåter for behandling av post- traumatisk stress-syndrom | |
NO20034123L (no) | Fremgangsmåte for behandling av brennstoff | |
NO20054700L (no) | Anvendelse av et fibrat og orlistat for behandling av fedme | |
DE60217653D1 (de) | Verwendung von melatonin zur behandlung der mit konzentrationsschwäche einhergehenden hyperaktivität | |
NO20043113L (no) | Fremgangsmate for behandling av benforstyrrelse | |
DE60233740D1 (de) | Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit | |
CY1106882T1 (el) | Τροποποιηση βητακυτταρουλινης | |
AU2003221350A1 (en) | Light amplifying device and method of manufacturing the device, light source device using the light amplifying device, light treatment device using the light source device, and exposure device using the light source device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |